PT-141 10MG $59
Peptides · CAS 189691-06-3 ≥99% Purity · HPLC verified

PT-141 10MG

Research-grade PT-141 (Bremelanotide) peptide. ≥99% purity, third-party verified via HPLC. For research and laboratory use only.

Save more · Bundle
1 vial · Single
Standard pricing
$59.00
$59.00 each
Save 10%
2 vials · Stock up
You save $11.80
$106.20
$118.00
★ Most popular
3 vials · Best value
You save $26.55
$150.45
$177.00
1
≥99% PurityHPLC verified Lab testedHPLC + MS Same-day shipOrder by 2pm PT
99.4% Purity
Certificate of Analysis
Third-party verified by HPLC & mass spectrometry
View COA
Curated picks

Frequently researched together

View all →
Identity

Compound information

What is PT-141?

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH). It functions as a non-selective melanocortin receptor agonist with preferential activity at MC3R and MC4R. Studied in laboratory settings for its central nervous system signaling profile, distinct from peripheral vasoactive pathways.

CAS Number 189691-06-3
Molecular Formula C50H68N14O10
Molecular Weight 1025.18 g/mol
Amino Acid Sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Half-Life ~2 hours (subcutaneous)
Source Synthetic cyclic peptide
Purity 99.4% (HPLC verified)
Form Lyophilized powder
Solubility Soluble in water, bacteriostatic water
Storage

Stability information

Long-term
−20°C
Lyophilized powder, sealed
Reconstituted
2–8°C
Up to 30 days when refrigerated
Shipping
Room temp
Stable in transit, lyophilized
Protection
Light · Moisture
Store sealed, away from light
Background

About this compound

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH), acting as a non-selective melanocortin receptor agonist. Studied in laboratory settings for its central nervous system signaling profile. Each vial contains 10mg lyophilized powder at ≥99% purity.

Specifications:

  • Purity: ≥99% (HPLC verified)
  • Form: Lyophilized powder
  • Storage: -20°C (long-term), 2-8°C (reconstituted)
  • Certificate of Analysis available

For research and laboratory use only. Not for human consumption.

Bibliography

Sources & references

01
Journal of Sexual Medicine · 2022
Selective melanocortin receptor agonists for hypoactive sexual desire disorder
Pfaus JG, Sadiq A, Spana C, Clayton AH
Review of bremelanotide pharmacology and central melanocortin signaling.
View source →
02
Annals of the New York Academy of Sciences · 2003
Discovery of bremelanotide, a selective MC3R/MC4R agonist
Molinoff PB, Shadiack AM, Earle D, et al.
Original receptor characterization of PT-141 selectivity.
View source →
03
Pharmacology Biochemistry and Behavior · 2007
Melanocortins and reproductive behaviour
Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P
Review of melanocortin receptor activity in CNS behavioral models.
View source →
More

Related products

View all →